Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Dubinett - Targeted Sequencing 2012

Dubinett - Targeted Sequencing 2012

358

No coordinating investigator defined.

UNKNOWN
Lung and Upper Aerodigestive Cancers Research Group

we propose to use targeted massively parallel DNA sequencing to identify somatic alterations within mutational hotspots in matched sets of primary lung tumors, premalignant lesions, and adjacent,histologically normal lung tissue.

1. Use targeted massively parallel DNA sequencing to assess the presence of mutations in specific genomic regions in matched sets of primary lung adenocarcinomas, premalignant lesions, and adjacent, histologically normal lung tissues obtained from the same patient. What is the prevalence of common lung-cancer-associated mutations in a panel of adenocarcinomas or premalignant lesions from the same patient? What is their baseline prevalence in lung tissue with no histologic indication of disease? 2. To identify mutations whose prevalence is significantly higher in tumors and premalignant lesions than in histologically normal lung tissue from the same patient, assess the variability of this prevalence among independent specimens within each patient, and examine the biological relationship between mutations whose prevalence is covariant across patients. Which mutations may be useful as early markers of lung cancer in patients with subclinical disease and which may be clinically actionable? How much does the spectrum of known cancer-associated mutations vary between independent premalignant lesions or different samples of the same primary tumor? Are there mutations that are frequently associated with each other or mutually exclusive, and if so, does this covariance reflect the biological relationship of the genes in which they occur?

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.